Herpes Esophagitis: Antiviral Choice and Duration in an Immunocompromised Patient
Biopsy-confirmed HSV esophagitis in a patient on maintenance immunosuppression after a kidney transplant raises two real, connected questions: whether to start with intravenous or oral antiviral therapy, and how to decide when a course this consequential is actually long enough to stop.
Simone K., 37, received a deceased-donor kidney transplant fourteen months ago after years on dialysis, and has thrown herself back into rock climbing at her local gym twice a week since, treating each new route she completes as a small, deliberate marker of how far she's come. She's maintained on tacrolimus, mycophenolate, and low-dose prednisone, and presented with eight days of worsening odynophagia and a low-grade fever, unable to keep down more than sips of water by the time she came in. Endoscopy showed multiple small, well-circumscribed ulcers with raised, volcano-like edges throughout the mid-to-distal esophagus — the classic appearance of HSV esophagitis rather than the larger, more confluent ulcers typical of CMV — and biopsy with immunohistochemistry confirmed HSV-1.
Her degree of oral intolerance and volume depletion argue for starting intravenous rather than oral therapy, at least initially: she's currently unable to reliably keep down oral intake, which makes oral bioavailability a real practical concern independent of which drug would otherwise be preferred. Acyclovir and valacyclovir (its oral prodrug, converted to acyclovir after absorption) work through the same mechanism — viral thymidine kinase-dependent activation followed by DNA polymerase inhibition — so once she can reliably tolerate oral intake, the choice becomes less about mechanism and more about dosing convenience and adherence. Duration in immunocompromised HSV esophagitis is typically longer than in an immunocompetent patient, and the real judgment call is less about the drug itself than about when her clinical and, ideally, endoscopic response is convincing enough to stop rather than continuing on a fixed calendar alone. The renal-dosing adjustment is quantifiable rather than precautionary. Acyclovir's clearance falls close to linearly with declining creatinine clearance, and under-adjusted dosing in a patient with reduced renal function is a well-described cause of acute neurotoxicity, distinct from the nephrotoxicity risk itself — two separate reasons the transplant team's direct involvement in her dosing, not just her tacrolimus levels, is a genuine safety requirement here rather than routine courtesy coordination.
Route now, duration later
Given that she can't reliably keep down oral intake right now, I'd start IV acyclovir rather than oral therapy. This isn't really a drug-choice question at this stage — acyclovir and valacyclovir work through the same mechanism, so once she can eat and drink consistently, we transition to oral valacyclovir for convenience. Right now, the practical issue is absorption reliability, not which agent is theoretically preferred.
I'd plan from the start for a longer course than the 7-10 days typical in an immunocompetent patient. In my experience managing HSV in transplant recipients, incompletely treated disease in someone this immunosuppressed tends to recur, and I'd rather set the expectation now that duration tracks her actual clinical response — resolved odynophagia, tolerating a normal diet — rather than a fixed calendar date we commit to today.
I agree with both of you, and I want to add one specific thing that needs active coordination rather than being assumed to take care of itself: acyclovir is renally cleared and has a real, dose-dependent nephrotoxicity risk. She's fourteen months out from a kidney transplant, already being monitored for tacrolimus levels, and I want acyclovir dosing adjusted to her actual renal function and reviewed alongside her tacrolimus levels by the transplant team directly, not managed as a separate, uncoordinated prescription.
A response-guided duration, as proposed, actually makes that coordination more important, not less — a longer course means more days of renal-clearance monitoring to get right, not fewer.
Agreed: IV acyclovir started now with renal dose-adjustment coordinated directly with the transplant team, transition to oral valacyclovir planned once she reliably tolerates oral intake, and total duration guided by her clinical response (resolved odynophagia, normal diet tolerance) rather than fixed in advance. Tacrolimus levels are being monitored alongside acyclovir dosing throughout, per the pharmacologist's explicit coordination request.